Synergy Pharma Cmn (SGYP) 5.61 $SGYP Synergy

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Synergy Pharma Cmn (SGYP) 5.61 $SGYP

Synergy Pharmaceuticals to Present at OctoberINVESTfest 2016
BusinessWire - Fri Sep 23, 8:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company will present at the OctoberINVESTfest Conference on Wednesday, September 28, 2016 at 11:30 a.m. Eastern Time at the New York Academy of Sciences in New York.
SGYP: 5.61 (+0.03)

Drug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences
PR Newswire - Thu Sep 15, 6:40AM CDT
The global Drug Manufacturers space has seen moderate growth over the last five years due to increased demand for medicines, especially from emerging economies. This morning, Stock-Callers.com has issued research reports on four equities, namely, Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and Apricus Biosciences Inc. (NASDAQ: APRI). Download the free research reports on these stocks today:
SGYP: 5.61 (+0.03), NVO: 44.88 (-0.69), PTX: 0.65 (+0.03), APRI: 0.35 (-0.05)

Synergy Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference
BusinessWire - Wed Sep 07, 8:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Rodman & Renshaw Conference on Monday, September 12, 2016 at 5:30 p.m. Eastern Time at the Lotte New York Palace Hotel in New York.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update
BusinessWire - Mon Aug 08, 4:00PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended June 30, 2016.
SGYP: 5.61 (+0.03)

Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 5.61 (+0.03), NVO: 44.88 (-0.69), DRRX: 1.70 (-0.04), BIOD: 0.45 (+0.03)

Synergy Pharmaceuticals to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Mon Aug 01, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
BusinessWire - Tue May 24, 12:36PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body's naturally occurring gastrointestinal (GI) peptide - uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sun May 22, 11:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sat May 21, 11:31AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating patients with chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
BusinessWire - Mon May 16, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
SGYP: 5.61 (+0.03)

Synergy Pharma reports 1Q loss
Automated Insights - Tue May 10, 5:20PM CDT
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Tuesday reported a loss of $59.9 million in its first quarter.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
BusinessWire - Tue May 10, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Mon May 09, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of common stock at a price of $3.00 per share.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Thu May 05, 7:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.
SGYP: 5.61 (+0.03)

Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What:  After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals  were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 5.61 (+0.03), AGN: 243.94 (+0.51), IRWD: 15.72 (-0.15)

These Stocks Are Starting To Catch Wall Street's Attention
ACCESSWIRE - Fri Apr 29, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else. Today we are taking a look at five companies which we believe could provide investors with potential upside volatility in the near term.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
BusinessWire - Wed Apr 27, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company's Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy since 2008, will assume responsibilities as Principal Financial Officer.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
BusinessWire - Tue Apr 26, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,2016 at 2:50 p.m. Eastern Time.
SGYP: 5.61 (+0.03), DB: 12.75 (-0.25)

Global Constipation Market: Vast Opportunity for New Drug Entry - Key Players are AstraZeneca, Ironwood Pharmaceuticals & Synergy Pharmaceuticals - Research and Markets
BusinessWire - Fri Apr 22, 5:18AM CDT
Research and Markets has announced the addition of the "Global Constipation Market Report: 2016 Edition" report to their offering.
SGYP: 5.61 (+0.03), IRWD: 15.72 (-0.15)

What's Behind Synergy Pharmaceuticals' Soaring Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 3:03PM CDT
Image source: Synergy Pharmaceuticals. What:  After reporting that the FDA has officially accepted its application for the approval of plecanatide, shares of Synergy Pharmaceuticals are gaining 10.5% at 3:30 p.m. EDT today. So what:...
SGYP: 5.61 (+0.03), AGN: 243.94 (+0.51), IRWD: 15.72 (-0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 116

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 45

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 186

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 179

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Allstate's October Cat Loss Lands at $232 Million Net

Updated Category News Views 75

October’s weather bill arrived without much poetry: $232 million in estimated catastrophe losses at Allstate. Reported on November 19, that figure falls to $184 million after tax, and it deserves a clear-eyed read rather than the usual insurance-stock theatrics. A single monthly catastrophe tally is not a verdict on the company, but it is absolutely part of the...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 21

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 174

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 190

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 65

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Global Gifts Retailing Market

Updated Category News Views 120

The Gifts Retailing Market is Evolving Rapidly The global gifts retailing industry is projected to experience substantial growth, with estimates indicating an increase of USD 11.01 billion from 2024 to 2028. Several influential factors are driving this trend, notably the rising demand for seasonal decorations and a stronger gifting culture. As consumers increasingly...

Continue Reading
Exploring the Risks Behind the Monumental Rise of Big Tech

Updated Category News Views 163

Understanding the Current Landscape of Big Tech Investment In recent discussions about the tech industry, significant concerns have bubbled to the surface regarding the sustainability of current market valuations. Analysts have pointed out that the optimism surrounding the surge in equity prices may be fueled by unrealistic expectations. John Hussman notably remarked on...

Continue Reading
Senator Markwayne Mullin Makes Notable Stock Purchase in LPL

Updated Category News Views 246

Senator Markwayne Mullin's Recent Stock Transactions Recent financial disclosures reveal that Senator Markwayne Mullin has made a significant investment in LPL Financial Holdings Inc (NASDAQ: LPLA). The purchase, valued between $233,016 and $670,000, was filed recently and adds to his active trading portfolio. This transaction indicates Mullin's ongoing interest in the...

Continue Reading
Pathward Financial: Sale of Insurance Business Extended

Updated Category News Views 123

Pathward Financial, Inc. (NASDAQ: CASH), known as Meta Financial Group in the past, extended the closing of its commercial insurance premium finance business sale to October 22, from an initial deadline of October 1. Traders were quick to sniff out that this delay wasn’t just a minor hiccup—it pointed to deeper operational challenges. Delays and What They Mean for...

Continue Reading
Vallourec's Major Supply Order from ADNOC Signals Growth

Updated Category News Views 198

Vallourec's Major Supply Agreement with ADNOC Vallourec, a global leader in premium seamless tubular solutions, has successfully secured a significant order from the Abu Dhabi National Oil Company (ADNOC). This order includes supplying over 30,000 tons of carbon steel tubulars and related accessories, prominently featuring VAM premium connections. This transaction forms...

Continue Reading